MedTrace Logo

Evaluation of Changes in Visual Acuity in Patients With Diabetic Macular Edema (DME) Starting Treatment With an Approved Anti-VEGF Therapy

NCT01771081 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 911

Last updated 2015-10-28

No results posted yet for this study

Summary

POLARIS : A non-interventional study in patients with diabetic macular edema (DME) with central involvement to assess the effectiveness of existing anti-vascular endothelial growth factor (anti-VEGF) treatment regimens.

Conditions

  • Ophthalmology
  • Macular Edema
  • Macular Degeneration

Interventions

DRUG

Ranibizumab (or other DME treatment)

Patients with DME having started treatment with an approved anti-VEGF therapy at or after 01 October 2012 and then continuing with this or any kind or no treatment

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-04-30
Primary Completion
2015-01-31
Completion
2015-04-30

Countries

  • France
  • Germany
  • Greece
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • United Kingdom

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01771081 on ClinicalTrials.gov